US Senator Sanders says middlemen won't punish Novo if it cuts weight-loss drug prices
Adds Lilly background in paragraph 7, CEO comment on working with PBMs, paragraph 11
By Ahmed Aboulenein and Patrick Wingrove
WASHINGTON, Sept 24 (Reuters) -U.S. Senator Bernie Sanders said on Tuesday he had commitments from the nation's top pharmacy benefit managers that they would expand coverage of Novo Nordisk's NOVOb.CO popular diabetes and weight-loss medicines if the company lowered the list prices.
Sanders said in opening remarks at a hearing of the Senate Committee on Health, Education, Labor and Pensions, which he chairs, that he received the commitments from UnitedHealth Group's UNH.N Optum, CVS Health's CVS.N Caremark and Cigna's CI.N Express Scripts.
"I have received commitments in writing from all of the major PBMs that if Novo Nordisk substantially reduced the list price for Ozempic and Wegovy, they would not limit coverage. In fact, all of them told me they would be able to expand coverage for these drugs if the list price was reduced," he said.
The announcement preempts an argument pharmaceutical companies often make against reducing their list prices. They have said such cuts would lead to narrower coverage because pharmacy middlemen, known as PBMs, are incentivized to include expensive drugs on formularies because they lead to larger rebates.
Sanders criticized Novo Nordisk CEO Lars Jorgensen, the hearing's sole witness, on why his company charges Americans more than any other country for Ozempic and Wegovy, which can cost more than $1,000 a month in the U.S.
Semaglutide, a drug in the GLP-1 class that is marketed as Wegovy for weight loss and Ozempic for type 2 diabetes, has been shown to help patients lose an average of 15% of their weight.
Sanders and other lawmakers have also been critical of the cost of Eli Lilly's LLY.N rival drugs Mounjaro and Zepbound.
Ozempic and Wegovy carry U.S. list prices of $935.77 and $1,349, respectively, for a month's supply, far higher than the respective $59 and $92 price tags they carry in some European countries, Sanders noted.
Ozempic costs have decreased about 40% since launch while those for Wegovy have similarly declined for people who receive discounts, Jorgensen said.
The Danish drugmaker's CEO did not commit to cutting prices for either medicine when Sanders asked him if he would given the PBM commitments.
"I don't know under which conditions such a promise comes. I haven't seen any of that," said Jorgensen. He said he would collaborate with the PBMs and would be "happy to do anything that helps patients" but expressed skepticism over PBMs making the drugs more affordable.
He said 99% of U.S. commercial insurance plans now cover Ozempic and around half cover Wegovy. More than 80% of U.S. patients with insurance coverage for the drugs pay less than $25 for a month's supply and 90% pay less than $50, he added.
"It is not our intention that anyone should pay the list price," which he called merely the starting point for negotiations with PBMs and insurance companies.
Sanders said the net prices were still too high.
"Under your best case scenario, the price you are charging Americans for Ozempic is still nearly $600, that's with all of the rebates and all of the discounts, that's over nine times as much as people in Germany pay for the product," he said.
Reporting by Ahmed Aboulenein in Washington and Patrick Wingrove in New York; Additional Reporting by Manas Mishra in Bengaluru; Editing by Edward Tobin, Emelia Sithole-Matarise and Bill Berkrot
Asset collegati
Ultime news
Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.
Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.
Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.
